远程医疗平台Hims & Hers Health最新季度销售额上升，该公司持续扩充治疗项目范围，订阅用户数量 也有所增长。 Dudum表示，GLP‑1类药物确实为业务增长提供了显著助力，但这类药物只是其全球化消费平台中单一 领域的单一疗法，而随着持续投入，该平台正变得更加强健、多元。 他称，Hims & Hers仅有一小部分订阅用户使用复方GLP‑1类药物，这表明平台的影响力远不止于减重 领域。 他补充道，尽管并非所有新业务都能达到减重业务的增长速度，但凭借超级碗广告后用户接受度的快速 提升，公司有信心睾酮治疗、更年期护理及检测服务业务在不久的将来年营收均突破1亿美元。 "这三大新业务板块不只是新增服务，更是我们与客户建立更深度联结、创造更多价值的起点。" 尽管这家远程医疗平台预计今年增长势头将延续，但其第一季度业绩指引低于华尔街预期。 截至当日收盘，其股价在过去一年累计下跌69.8%。 这份财报发布之际，Hims & Hers正面临诺和诺德提起的诉讼，后者要求禁止该公司销售其减重药物的 仿制品。诺和诺德指控Hims & Hers侵犯司美格鲁肽相关专利，而Hims & Hers则批评该诉讼是在打压平 价药物选 ...

Hims & Hers Health (NYSE:HIMS) Q4 2025 Earnings call February 23, 2026 05:00 PM ET Company ParticipantsAndrew Dudum - Co-founder and CEOBill Newby - Head of Investor RelationsEric Percher - Partner of Pharma Supply Chain and Digital HealthGlen Santangelo - Managing DirectorMaria Ripps - Managing Director of Equity ResearchMark Mahaney - Senior Managing Director and Head of Internet ResearchYemi Okupe - CFOConference Call ParticipantsBrian Tanquilut - Senior Analyst of Healthcare Services and Digital Health ...

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $618 million, representing a year-over-year growth rate of 28% [25] - For the full fiscal year 2025, revenue reached $2.35 billion, reflecting a year-over-year growth rate of 59% [25] - Adjusted EBITDA for 2025 increased nearly 80% year-over-year to $318 million, with an Adjusted EBITDA margin of 14% [31] - Net income for the full year increased to $128 million, compared to the previous year [34] Business Line Data and Key Metrics Changes - The Hims brand in the US saw over 30% year-over-year revenue growth in 2025, despite a pivot away from generic sexual solutions [26] - The Hers brand continued to display triple-digit revenue growth, accounting for nearly 40% of U.S. revenue [27] - Approximately 65% of subscribers were utilizing a personalized treatment by the end of 2025, with monthly revenue per average subscriber increasing 11% year-over-year to $83 [24][25] Market Data and Key Metrics Changes - International revenue grew almost 400% year-over-year to $134 million, with expectations for this segment to become a more meaningful portion of overall revenue [30] - The company expects at least $200 million in revenue contributions from international markets in 2026, including from the acquisition of Eucalyptus [48] Company Strategy and Development Direction - The company aims to achieve $6.5 billion in revenue and $1.3 billion in Adjusted EBITDA by 2030, focusing on consumer-centric healthcare [22] - Investments in technology and infrastructure are prioritized to enhance personalized care and expand operational capabilities [19][38] - The company plans to deepen its international presence and aims for a unified brand across major markets within the next 1-2 years [54] Management's Comments on Operating Environment and Future Outlook - Management believes the healthcare system must evolve towards a consumer-oriented model, similar to platforms like Netflix and Spotify [6] - The company is confident in its ability to navigate regulatory scrutiny and maintain growth through diverse offerings beyond GLP-1 treatments [56] - Management anticipates strong demand for weight loss solutions and expects subscriber growth to remain robust throughout 2026 [45] Other Important Information - The company has invested over $300 million in facilities over the last three years, expanding its operational footprint to over 1 million square feet [19] - The acquisition of Eucalyptus is expected to enhance the company's international capabilities and contribute significantly to revenue growth [43] Q&A Session Summary Question: What are the long-term priorities for global growth with the acquisition of Eucalyptus? - The company aims to target 10 key markets globally and achieve over $1 billion in incremental international revenue within a few years [54] Question: How will the company manage risks from potential regulatory scrutiny on GLP-1s? - Management emphasizes that the majority of revenue comes from offerings outside of weight loss and plans to continue expanding its diverse offerings [56]

Financial Data and Key Metrics Changes - LifeMD reported consolidated revenue growth of 13% year-over-year to $60.2 million for Q3 2025, with telehealth revenue increasing 18% to $47.3 million [18] - Adjusted EBITDA for the quarter was $5.1 million, up from $4.3 million in the prior year, while telehealth adjusted EBITDA grew 30% to $2.9 million [19][20] - The company ended the quarter with $23.8 million in cash and no debt, marking the strongest balance sheet in its history [20] Business Line Data and Key Metrics Changes - The RexMD business added approximately 10,000 net new subscribers, rebounding from previous lows, with 8,000 of these coming from the sexual health segment [4][43] - Telehealth subscriber growth remained strong, with active subscribers increasing 14% year-over-year to over 310,000 [18] - Weight management continues to represent over 50% of total revenue, although there was a slight sequential decline in subscriber base [23] Market Data and Key Metrics Changes - The company is positioned to offer branded GLP-1 therapies at significantly reduced prices, with Wegovy and Ozempic available for $199 for the first two doses, a 60% reduction from current prices [8] - The anticipated approval of the Wegovy pill is expected to broaden access and accelerate demand, with estimates suggesting a potential market expansion of 25-50% due to patient preference for oral medications [56] Company Strategy and Development Direction - LifeMD's strategic priorities for 2026 include accelerating growth in weight management, scaling women's and behavioral health businesses, and launching a unified LifeMD platform [6] - The company aims to leverage collaborations with Novo Nordisk and Eli Lilly to enhance its competitive advantage in the GLP-1 space [7] - LifeMD is investing in a 503A compounding pharmacy to improve margins and control over patient experience, which is expected to drive growth across multiple health categories [11][55] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about 2026, highlighting the potential for improved pricing and coverage for branded therapies, which could significantly enhance revenue streams [25][30] - The competitive landscape in the weight management category remains challenging due to low-cost compounded products, but management believes that maintaining a focus on high-quality offerings will create long-term shareholder value [7][41] - The integration of insurance coverage is expected to positively impact customer acquisition costs and overall business performance [31] Other Important Information - The company divested its majority interest in WorkSimpli, strengthening its balance sheet and allowing it to focus solely on virtual care and pharmacy [5] - LifeMD is launching a new consumer-facing app and website, which is anticipated to enhance cross-selling capabilities and improve patient retention [52] Q&A Session Summary Question: Can you talk about the mix of telehealth product revenue, especially in weight loss? - The weight management segment still constitutes over 50% of total revenue, with a slight sequential decline in subscriber base noted [23] Question: How much of the growth in RexMD is driven by men's HRT versus ED? - Approximately 8,000 of the 10,000 new subscribers came from the sexual health business, primarily ED [43] Question: What impact do you expect from the approval of oral obesity products? - The Wegovy pill is expected to significantly expand the market, with estimates suggesting a 25-50% increase in patient uptake due to preference for oral medications [56] Question: How will insurance coverage affect your revenue? - A significant percentage of patients currently drop out due to lack of insurance coverage, and increased coverage is expected to have a massive positive impact on revenue [31] Question: What are the expectations for telehealth margins going forward? - Margins may slightly decline due to a shift in business mix, but all new offerings are expected to be accretive to the bottom line [46]